These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16837196)

  • 1. Structure-activity relationships for the linker in a series of pyridinyl-alkynes that are antagonists of the metabotropic glutamate receptor 5 (mGluR5).
    Bach P; Nilsson K; Svensson T; Bauer U; Hammerland LG; Peterson A; Wållberg A; Osterlund K; Karis D; Boije M; Wensbo D
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4788-91. PubMed ID: 16837196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new series of pyridinyl-alkynes as antagonists of the metabotropic glutamate receptor 5 (mGluR5).
    Bach P; Nilsson K; Wållberg A; Bauer U; Hammerland LG; Peterson A; Svensson T; Osterlund K; Karis D; Boije M; Wensbo D
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4792-5. PubMed ID: 16839764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships of fluorinated (E)-3-((6-methylpyridin-2-yl)ethynyl)cyclohex-2-enone-O-methyloxime (ABP688) derivatives and the discovery of a high affinity analogue as a potential candidate for imaging metabotropic glutamate recepors subtype 5 (mGluR5) with positron emission tomography (PET).
    Baumann CA; Mu L; Johannsen S; Honer M; Schubiger PA; Ametamey SM
    J Med Chem; 2010 May; 53(10):4009-17. PubMed ID: 20411954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia.
    Govek SP; Bonnefous C; Hutchinson JH; Kamenecka T; McQuiston J; Pracitto R; Zhao LX; Gardner MF; James JK; Daggett LP; Rowe BA; Schaffhauser H; Bristow LJ; Campbell UC; Rodriguez DE; Vernier JM
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4068-72. PubMed ID: 16005222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and biological profile of 4-(1-aryltriazol-4-yl)-tetrahydropyridines as an orally active new class of metabotropic glutamate receptor 1 antagonist.
    Ito S; Satoh A; Nagatomi Y; Hirata Y; Suzuki G; Kimura T; Satow A; Maehara S; Hikichi H; Hata M; Kawamoto H; Ohta H
    Bioorg Med Chem; 2008 Nov; 16(22):9817-29. PubMed ID: 18849168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships for negative allosteric mGluR5 modulators.
    Kaae BH; Harpsøe K; Kvist T; Mathiesen JM; Mølck C; Gloriam D; Jimenez HN; Uberti MA; Nielsen SM; Nielsen B; Bräuner-Osborne H; Sauerberg P; Clausen RP; Madsen U
    ChemMedChem; 2012 Mar; 7(3):440-51. PubMed ID: 22267204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationship of thiopyrimidines as mGluR5 antagonists.
    Hammerland LG; Johansson M; Malmström J; Mattsson JP; Minidis AB; Nilsson K; Peterson A; Wensbo D; Wållberg A; Osterlund K
    Bioorg Med Chem Lett; 2006 May; 16(9):2467-9. PubMed ID: 16481165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3-[Substituted]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitriles: identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists.
    Tehrani LR; Smith ND; Huang D; Poon SF; Roppe JR; Seiders TJ; Chapman DF; Chung J; Cramer M; Cosford ND
    Bioorg Med Chem Lett; 2005 Nov; 15(22):5061-4. PubMed ID: 16183275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a potent and brain penetrant mGluR5 positive allosteric modulator.
    Ritzén A; Sindet R; Hentzer M; Svendsen N; Brodbeck RM; Bundgaard C
    Bioorg Med Chem Lett; 2009 Jun; 19(12):3275-8. PubMed ID: 19443216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization and modeling of the binding sites of novel 1,3-bis(pyridinylethynyl)benzenes as metabotropic glutamate receptor 5-selective negative allosteric modulators.
    Mølck C; Harpsøe K; Gloriam DE; Clausen RP; Madsen U; Pedersen LØ; Jimenez HN; Nielsen SM; Mathiesen JM; Bräuner-Osborne H
    Mol Pharmacol; 2012 Nov; 82(5):929-37. PubMed ID: 22899869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists.
    Kulkarni SS; Zou MF; Cao J; Deschamps JR; Rodriguez AL; Conn PJ; Newman AH
    J Med Chem; 2009 Jun; 52(11):3563-75. PubMed ID: 19445453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scaffold hopping from pyridones to imidazo[1,2-a]pyridines. New positive allosteric modulators of metabotropic glutamate 2 receptor.
    Tresadern G; Cid JM; Macdonald GJ; Vega JA; de Lucas AI; García A; Matesanz E; Linares ML; Oehlrich D; Lavreysen H; Biesmans I; Trabanco AA
    Bioorg Med Chem Lett; 2010 Jan; 20(1):175-9. PubMed ID: 19932615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.
    Poon SF; Eastman BW; Chapman DF; Chung J; Cramer M; Holtz G; Cosford ND; Smith ND
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5477-80. PubMed ID: 15482907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 2: 4-thiopyridyl acetophenones as non-tetrazole containing mGlu2 receptor potentiators.
    Pinkerton AB; Cube RV; Hutchinson JH; James JK; Gardner MF; Schaffhauser H; Rowe BA; Daggett LP; Vernier JM
    Bioorg Med Chem Lett; 2004 Dec; 14(23):5867-72. PubMed ID: 15501058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between brain/plasma ratios and efficacy in neuropathic pain models of selective metabotropic glutamate receptor 1 antagonists.
    Zheng GZ; Bhatia P; Kolasa T; Patel M; El Kouhen OF; Chang R; Uchic ME; Miller L; Baker S; Lehto SG; Honore P; Wetter JM; Marsh KC; Moreland RB; Brioni JD; Stewart AO
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4936-40. PubMed ID: 16809035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonists at metabotropic glutamate receptor subtype 5: structure activity relationships and therapeutic potential for addiction.
    Carroll FI
    Ann N Y Acad Sci; 2008 Oct; 1141():221-32. PubMed ID: 18991960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists.
    Chua PC; Nagasawa JY; Bleicher LS; Munoz B; Schweiger EJ; Tehrani L; Anderson JJ; Cramer M; Chung J; Green MD; King CD; Reyes-Manalo G; Cosford ND
    Bioorg Med Chem Lett; 2005 Oct; 15(20):4589-93. PubMed ID: 16115767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.
    Huang D; Poon SF; Chapman DF; Chung J; Cramer M; Reger TS; Roppe JR; Tehrani L; Cosford ND; Smith ND
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5473-6. PubMed ID: 15482906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, radiolabeling, in vitro and in vivo evaluation of [18F]-FPECMO as a positron emission tomography radioligand for imaging the metabotropic glutamate receptor subtype 5.
    Lucatelli C; Honer M; Salazar JF; Ross TL; Schubiger PA; Ametamey SM
    Nucl Med Biol; 2009 Aug; 36(6):613-22. PubMed ID: 19647167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists.
    Bonnefous C; Vernier JM; Hutchinson JH; Chung J; Reyes-Manalo G; Kamenecka T
    Bioorg Med Chem Lett; 2005 Feb; 15(4):1197-200. PubMed ID: 15686941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.